ConductScience.org, home

Paper41007722

STING-Activating Nanoparticles Combined with PD-1/PD-L1 Blockade: A Synergistic Approach in Cancer Immunotherapy.

Bartusik-Aebisher D and 2 others. Biomedicines, 2025. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. STING-Activating Nanoparticles Combined with PD-1/PD-L1 Blockade: A Synergistic Approach in Cancer Immunotherapy. Papers, record 41007722. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007722

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
STING-Activating Nanoparticles Combined with PD-1/PD-L1 Blockade: A Synergistic Approach in Cancer Immunotherapy.
PubMed
Journal
Biomedicines
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
3.27, provisional
iCite
Revised in PubMed
2025-09-30
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bartusik-Aebisher DDorotahttps://orcid.org/0000-0002-5557-5464
2Rogóż KKacperhttps://orcid.org/0009-0002-7999-3449
3Aebisher DDavidhttps://orcid.org/0000-0002-2661-6570

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References132

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128187290Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell2017https://conductscience.org/library/papers/28187290PubMed
239735733Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment.JCO Oncol Adv2024https://conductscience.org/library/papers/39735733PubMed
338999073Agonists and Inhibitors of the cGAS-STING Pathway.Molecules2024https://conductscience.org/library/papers/38999073PubMed
440086770AI-driven innovations in smart multifunctional nanocarriers for drug and gene delivery: A mini-review.Crit Rev Oncol Hematol2025https://conductscience.org/library/papers/40086770PubMed
540500702Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy.Mol Cancer2025https://conductscience.org/library/papers/40500702PubMed
633188827Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors.J Control Release2021https://conductscience.org/library/papers/33188827PubMed
737607938Cholesterol removal improves performance of a model biomimetic system to co-deliver a photothermal agent and a STING agonist for cancer immunotherapy.Nat Commun2023https://conductscience.org/library/papers/37607938PubMed
840052211Mitigating Doxorubicin-Induced Cardiotoxicity and Enhancing Anti-Tumor Efficacy with a Metformin-Integrated Self-Assembled Nanomedicine.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40052211PubMed
934716197Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.Clin Cancer Res2022https://conductscience.org/library/papers/34716197PubMed
1037779919Combination of irinotecan silicasome nanoparticles with radiation therapy sensitizes immunotherapy by modulating the activation of the cGAS/STING pathway for colorectal cancer.Mater Today Bio2023https://conductscience.org/library/papers/37779919PubMed
1138660408RGD targeted magnetic ferrite nanoparticles enhance antitumor immunotherapeutic efficacy by activating STING signaling pathway.iScience2024https://conductscience.org/library/papers/38660408PubMed
1236282874Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.Clin Cancer Res2023https://conductscience.org/library/papers/36282874PubMed
1340294811Mitochondria-targeted manganese-based mesoporous silica nanoplatforms trigger cGAS-STING activation and sensitize anti PD-L1 therapy in triple-negative breast cancer.Acta Biomater2025https://conductscience.org/library/papers/40294811PubMed
1440190094Nanosized Shikonin Disrupts Tumor-Cell Mismatch Repair and Synergizes with Manganese to Sensitize Squamous Carcinoma to Immunotherapy.ACS Nano2025https://conductscience.org/library/papers/40190094PubMed
1539747173Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung.Nat Commun2025https://conductscience.org/library/papers/39747173PubMed
1640415537Grapefruit Extracellular-Vesicle-Derived Nanodrug Loading Three-Functional Platinum(IV) Conjugates with Enhanced Targeting and TME Modulating Properties.J Med Chem2025https://conductscience.org/library/papers/40415537PubMed
1738117852ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer.Proc Natl Acad Sci U S A2023https://conductscience.org/library/papers/38117852PubMed
1834207137Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment.J Pers Med2021https://conductscience.org/library/papers/34207137PubMed
1936510011The cGAS-STING pathway and cancer.Nat Cancer2022https://conductscience.org/library/papers/36510011PubMed
2040126217Ultrasound-Responsive Nanobubbles for Breast Cancer: Synergistic Sonodynamic, Chemotherapy, and Immune Activation through the cGAS-STING Pathway.ACS Appl Mater Interfaces2025https://conductscience.org/library/papers/40126217PubMed

See all 132 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42738166Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches.Materials (Basel)2026https://conductscience.org/library/papers/42738166PubMed
42029811Silica based nanocarriers for combination immunotherapy targeting the tumor immune microenvironment.Drug Deliv Transl Res2026https://conductscience.org/library/papers/42029811PubMed
41638631Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions.J Adv Res2026https://conductscience.org/library/papers/41638631PubMed
41516128Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy.Int J Mol Sci2025https://conductscience.org/library/papers/41516128PubMed
41514360Tumor-homing cerium nanozyme platform enables coordinated drug release and STING activation for bladder cancer treatment.J Nanobiotechnology2026https://conductscience.org/library/papers/41514360PubMed
41501823Cell-type specific activation of the cGAS-STING pathway in tumor immunotherapy: mechanisms and therapeutic implications.J Transl Med2026https://conductscience.org/library/papers/41501823PubMed
41150783The Role of MALDI-TOF Mass Spectrometry in Photodynamic Therapy: From Photosensitizer Design to Clinical Applications.Curr Issues Mol Biol2025https://conductscience.org/library/papers/41150783PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CGAS115004PubTator's text mininghttps://conductscience.org/library/genes/115004NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
STING1340061PubTator's text mininghttps://conductscience.org/library/genes/340061NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41007722

GET https://conductscience.org/api/papers/v1/41007722/references?page=2